Coeptis Therapeutics Holdings Inc Ordinary Shares COEP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COEP is a good fit for your portfolio.
News
-
Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
-
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
-
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Trading Information
- Previous Close Price
- $0.33
- Day Range
- $0.32–0.34
- 52-Week Range
- $0.29–2.19
- Bid/Ask
- $0.31 / $0.39
- Market Cap
- $12.09 Mil
- Volume/Avg
- 93,836 / 266,971
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.coeptistx.com
Valuation
Metric
|
COEP
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.74 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
COEP
|
---|---|
Quick Ratio | 1.68 |
Current Ratio | 1.76 |
Interest Coverage | −196.49 |
Quick Ratio
COEP
Profitability
Metric
|
COEP
|
---|---|
Return on Assets (Normalized) | −258.49% |
Return on Equity (Normalized) | −533.87% |
Return on Invested Capital (Normalized) | −364.44% |
Return on Assets
COEP
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zjjdffdrc | Jhrz | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pfzjzkjwk | Jflspgf | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bczwcmw | Ndmmq | $97.3 Bil | |
MRNA
| Moderna Inc | Spbglgnt | Cdnj | $42.7 Bil | |
ARGX
| argenx SE ADR | Vtwrbtjgs | Vsrk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pyqvtlg | Qkj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fnfszgsw | Nmnvml | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hvqngmxgj | Kskyz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qmgcmbzhd | Xksbtv | $12.6 Bil | |
INCY
| Incyte Corp | Rvblxhrq | Zpdmfy | $11.8 Bil |